Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
RESEARCH TOOLSreports
Holding PRAX?
Track your performance easily
PRAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.01 - $67.93
Previous Close$61.97
Volume316.13K
Average Volume (3M)257.91K
Market Cap
$1.10B
Enterprise Value$750.47M
Total Cash (Recent Filing)$351.88M
Total Debt (Recent Filing)$1.95M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 06, 2024EPS Estimate
-$1.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.27
Shares Outstanding17,757,069
10 Day Avg. Volume298,108
30 Day Avg. Volume257,908
Standard Deviation0.34
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.75
Price to Sales (P/S)621.35
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue423.76
Enterprise Value/Gross Profit306.69
Enterprise Value/Ebitda-6.13
Forecast
1Y Price Target
$146.00Price Target Upside124.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Praxis Precision Medicines News
PremiumCompany Announcements
Praxis Precision Updates Executive Severance Packages
PremiumCompany Announcements
Praxis Precision Medicines’ Promising EMBOLD Study OutcomesBulls Say, Bears Say
Bulls Say
Clinical Data And SafetyEarly impressive clinical data for PRAX-628 should translate well in FOS P2b and could provide a differentiated safety/profile in this polypharmacy market.
Commercial PotentialUlixacaltamide's upcoming P3 readout warrants particular attention given its significant commercial potential.
Seizure TreatmentRelutrigine offers robust seizure reduction in the first few weeks of treatment and unprecedented seizure-free periods for SCN8A and SCN2A DEE patients in POC study.
Bears Say
EarningsPRAX reported 2Q24 revenue of $0.4 million, significantly lower than the consensus estimate of $1 million.
Financial PerformancePRAX reported an EPS of -$1.74, which is a 25% decrease compared to the consensus EPS of -$2.31, driven by a lower net income margin.
Investor ExpectationsInvestors expect negative data to potentially drive the stock down by 40%.
---
Ownership Overview
Currently, No data available
---
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $13.01 and its highest was $67.93 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Currently, no data Available
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Nov 06, 2024 which is in 22 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Aug 13, 2024. The company reported -$1.74 earnings per share for the quarter, beating the consensus estimate of -$2.315 by $0.575.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -$1.94.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 17,757,069 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$1.74 in its last earnings report, beating expectations of -$2.315. Following the earnings report the stock price went up 0.81%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Among the largest hedge funds holding Praxis Precision Medicines’s share is RA Capital Management. It holds Praxis Precision Medicines’s shares valued at 51M.
---
Praxis Precision Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$146.00 (124.62% Upside)
$146.00 (124.62% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 277.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
190.93%
12-Months-Change
Fundamentals
Return on Equity
-47.16%
Trailing 12-Months
Asset Growth
230.39%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for patients and families affected by complex and debilitating brain disorders. The firm's pipeline covers PRAX-114, PRAX-944, PRAX-562, and PRAX-222 among others.
---
PRAX Earnings Call
Q2 2024
0:00 / 0:00
---
PRAX Stock 12 Month Forecast
Average Price Target
$146.00
▲(124.62% Upside)
Technical Analysis
Best Analysts Covering PRAX
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+81.74%
reiterated a buy rating 12 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +81.74% per trade.
---